Alzheimer’s Disease Trials (AD)

---

The following are ongoing Alzheimer’s Disease clinical trials in Canada:

A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects With Early Alzheimer’s Disease

Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer’s Disease (AD)

A Study of LY3303560 in Participants With Early Symptomatic Alzheimer’s Disease

A Study of LY3002813 and LY3202626 in Participants With Early Symptomatic Alzheimer’s Disease

A Study of Donanemab (LY3002813) in Participants With Early Alzheimer’s Disease

A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer’s Disease (INVOKE-2)

Safety, and Efficacy of a New Buccal Film of Montelukast in Patients With Mild to Moderate Alzheimer’s Disease (BUENA)

Efficacy and Safety Study of AL002 in Participants With Early Alzheimer’s Disease

Safety, and Efficacy Study of Sodium Oligomannate (GV-971) in Treatment of Mild to Moderate Alzheimer’s Disease

Study of ANAVEX2-73 for Treatment of Early Alzheimer’s Disease)

A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer’s Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205